Skip to main content

Homepage

Latest News

IMI launches IMI2 - Call 17

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of IMI2 - Call 17. The total budget of the Call is over EUR 80 million. Half of this comes from the European Commission’s Horizon 2020 programme and will fund the participation in the projects of universities, small and medium-sized companies, patient groups etc. The other half comes from large pharmaceutical companies and IMI Associated Partners, who do not receive EU funding through IMI but finance their own participation in our projects.

/news-eventspress-releases/open-access-drug-development-tools-feature-new-imi-call-proposals

Sign up for the IMI2 - Call 17 webinars

Sign up for the IMI2 - Call 17 webinars  more

Find out about IMI's potential future Call topics

Find out about IMI's potential future Call topics  more

TRISTAN project reveals impact of drug side effects in lungs

TRISTAN project reveals impact of drug side effects in lungs  more

 

 

IMI BROCHURE HIGHLIGHTS PROJECT SUCCESSES

IMI projects are accelerating the medicines development process, generating new scientific insights, and developing resources for open use by the research community. Furthermore, some of our projects are already delivering direct benefits to patients. Interested in concrete numbers and examples? Find out more about the impact and outputs of our projects in our new brochure, and learn how we are 'Carrying the torch for medical innovation'.

 more

dna.jpg

 

 

 

WATCH IMI video

Carrying the torch for medical innovation

Diseases keep changing, and infections we treated for decades can once again kill. By bringing together researchers from the public and private sectors, we are working to speed up medicines development and turn knowledge into treatments. Watch our video and share it!